Tags
- 04
- 1:1
- 24 Weeks
- 2A
- 3
- 4
- 52 Weeks
- 6
- A
- Abnormal
- Abnormality
- Activities of daily living
- Aducanumab
- Advanced
- Advances
- Adverse
- Adverse event
- Adverse Events
- Ageing
- Aging
- Aid
- AIDS
- Alpha
- Alzheimer
- Alzheimer's Association
- Alzheimer's disease
- Amend
- Amendment
- Amyloid
- Amyloid beta
- Amyloid-related imaging abnormalities
- An
- Analysis
- Analysis plan
- And 1
- Andromeda II
- Antibody
- Appreciable
- Approved
- Asse
- Assessment
- Association
- Await
- Based on
- Baseline
- Benefit
- BIND
- Blinded
- Blinded experiment
- Block
- Block size
- Boxes
- Brain
- Cascade
- Categories
- Categorization
- Cerebral
- Characteristic
- Clearance
- Clinical
- Clinical case definition
- Clinical Dementia Rating
- Clinical Practice
- Clinical trial
- Clinical Trials
- ClinicalTrials.gov
- Cognition
- Cognitive
- Cognitive deficit
- Collected
- Combined
- Completion
- Composed
- Computer-generated
- Conducting
- Confidence interval
- Consecutive
- Consent
- Considerable
- Considered
- Cooperative
- Criteria
- Data
- Database
- Death
- Decisions
- Declaration
- Declaration of Helsinki
- Defined
- Dementia
- Demography
- Deposit
- Deposit account
- Development
- Differences
- Discontinuation
- Discretion
- Disease
- Disease research
- D.O.E.
- Dose
- Drug
- Drug development
- Edema
- Efficacy
- Effusion
- Eligibility
- Eligibility criteria
- Emission
- Enrollment
- Equal
- Equals sign
- Étable
- Ethics
- Ethnic group
- Ethnicity
- Every
- Examination
- Exclusion
- Exploratory
- Failure
- Figure 1
- Fixed
- G1
- Good clinical practice
- Greater
- Guideline
- Guidelines
- Hallmark
- Harmonization
- Helsinki
- Hemorrhage
- Hemosiderin
- Hypothesis
- Identifier
- If
- Imaging
- Immunoglobulin G
- Impairment
- Inclusion and exclusion criteria
- Indiana State Road 8
- Indication
- Inequality
- Infusion
- Infusions
- Integration
- Interactive
- International
- Interruption
- Intracerebral hemorrhage
- Intravenous therapy
- Investigator
- Last Alliance
- Least squares
- Less
- LSm
- Magnetic
- Magnetic resonance
- Magnetic resonance imaging
- Manner
- Matter
- Measurement
- Medical
- Medical guideline
- Medical research
- Mild cognitive impairment
- Mini–Mental State Examination
- MMSE
- Modified
- Monitoring
- Monoclonal
- Monoclonal antibody
- Mri
- MRIS
- National Institute
- Neurofibrillary tangle
- Normal distribution
- N-terminus
- One Beat
- Only
- Ontario Highway 2
- Originally
- Over
- Oversight
- Participation
- Partner
- Partners
- Pathological
- Pathology
- Patient
- Performance
- Permanent
- Pet
- Phase
- PHASE 2
- Phase 2 trial
- Phase 3
- Phase 3 trial
- Placebo
- Placebo-controlled study
- Plaque
- Plaque removal
- Population
- Positron
- Positron emission
- Positron emission tomography
- Presence
- Primary
- Procedure
- Progression
- Projection screen
- Promising
- Protein
- Protocol
- Quantitative
- Race
- Radiographic imaging
- Radiography
- Randomization
- Randomized controlled trial
- Randomness
- Range
- Rating scale
- Reaction
- Reads
- Registration
- Regulation
- Regulatory requirements
- Relevance
- Remainder
- Removal
- Requirement
- Research
- Resolution
- Resonance
- Result
- Review Board
- Safety
- Safety monitoring
- Scale
- Scan
- Schedule
- Score
- Scores
- Screening
- Secondary
- Self-report study
- Sensor
- Severity
- Siderosis
- Single
- Sites
- Solubility
- Speed
- Staatsexamen
- Stabilization
- Statistical analysis plan
- Statistical significance
- Statistical testing
- Statistics
- Stratification
- Study partner
- Study protocol
- Summation
- Superficial
- Superficial siderosis
- Supplement
- Switched
- Symptomatic
- Symptoms
- Systems
- Tangle
- Tangles
- Target
- Targets
- Tau protein
- The brain
- The Combined
- The Declaration
- The first
- The international
- Therapy
- The Spill Canvas
- The trial
- Three
- Three Deaths
- Tomography
- Treat
- Treatment effect
- Trial
- Trials
- Truncation
- Type I and type II errors
- Up to eleven
- V
- Visit
- Visual
- Web response
- White matter
- White matter disease
- Women